Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.60 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.60 |
| ▸ | HCK | P08631 | 7/20 | 0.60 |
| ▸ | SRC | P12931 | 9/20 | 0.58 |
| ▸ | GSK3A | P49840 | 7/20 | 0.58 |
| ▸ | SYK | P43405 | 6/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.58 |
| ▸ | BRAF | P15056 | 3/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20060691 | 0.91 | MAPK14 (0.65) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL12288114 | 0.90 | MAPK14 (0.75) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL20060696 | 0.89 | MAPK14 (0.65) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL19841213 | 0.89 | MAPK14 (0.68) | MAPK14MAPK12HCKSRCTNF | |
| SCHEMBL20060660 | 0.88 | MAPK14 (0.64) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL14700450 | 0.88 | MAPK14 (0.66) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL20036718 | 0.88 | MAPK14 (0.64) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL20060711 | 0.87 | MAPK14 (0.65) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL19388864 | 0.87 | MAPK14 (0.78) | MAPK14MAPK12HCKSRCGSK3A | |
| SCHEMBL20036713 | 0.87 | MAPK14 (0.61) | MAPK14MAPK12HCKSRCGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160115152-A1 | Novel Compounds | RESPIVERT LTD. (GB) | 2016-04-28 | — | — | US | disclosed |
| US-9260410-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2016-02-16 | — | — | US | disclosed |
| US-20130040995-A1 | NOVEL COMPOUNDS | RESPIVERT LTD. (GB) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115152-A1 | Novel Compounds | ESRRA, ESRRB, LTB4R | MAPK14 4125/4885MAPK12 3076/4885HCK 4810/4885 |
| US-20130040995-A1 | NOVEL COMPOUNDS | ESRRA, ESRRB, LTB4R | MAPK14 4125/4885MAPK12 3076/4885HCK 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.